摘要
背景:细菌对常用抗菌药物的耐药性越来越大,迫使人们寻求替代或支持治疗感染的方法。靶向毒力因子就是其中之一。方法.细菌基因蛋白的强烈参与毒力和在许多情况下,缺乏对性功能鉴定病原菌。htras法下应力保护细胞成功的条件以及他们直接参与的主机的入侵。后者的功能主要是由最近发现的胞外部分HtrA玩。本文旨在对电动汽车进行综述。htras评价作为治疗目标,包括设计化学抑制剂和疫苗。 方法:我们对同行科学文献的书目数据库进行了彻底的研究。 结果:共纳入一百六十四篇论文。首先,我们简要地总结了关键的结构和功能已知HtrA proteins在外HtrA分数特别关注性能。然后我们提供的努力和进步目标病原菌htras作为保证的概述抗菌治疗。在某些情况下,取得了令人鼓舞的结果,htraspecific抑制剂保护组织免受破坏和杀死细菌的应用。也有令人鼓舞的报告关注荷兰HtrA使用在一些疾病模型的一种保护性抗原最近发表。 结论:本文的研究结果表明,出口HtrA蛋白由于其可达性很有前景的治疗靶点,在毒力和免疫原性的意义。然而此外,还需要进行广泛的研究,以开发安全的抗菌治疗。
关键词: Serine protease,变构酶,细菌感染,毒力因子,疫苗研制,选择性抑制,治疗性化合物的设计。
Current Medicinal Chemistry
Title:The Extracellular Bacterial HtrA Proteins as Potential Therapeutic Targets and Vaccine Candidates
Volume: 24 Issue: 20
关键词: Serine protease,变构酶,细菌感染,毒力因子,疫苗研制,选择性抑制,治疗性化合物的设计。
摘要: Background: An increasing resistance of bacteria to the commonly used antimicrobials forces to search for alternative or supportive ways to cure infections. Targeting virulence factors is one of such approaches. The bacterial HtrA proteins are strongly involved in virulence and the lack of functional HtrA in many cases impairs invasiveness of pathogens. HtrAs act by protecting the cells under stressful conditions as well as they take direct part in invasion of the host. The latter function is played predominantly by the recently identified extracellular fraction of HtrA. This review aims to evaluate HtrAs as therapeutic targets, including design of chemical inhibitors and vaccines.
Methods: We undertook a thorough search of bibliographic databases for peer-reviewed scientific literature. Results: One hundred and sixty-four papers were included in the review. First, we briefly summarized key structural and functional properties of known HtrA proteins with the special focus on the extracellular HtrA fraction. Then we provided an overview of efforts and advancements to target HtrAs of pathogenic bacteria as a promising antimicrobial therapy. In some cases, encouraging results were obtained and application of HtrAspecific inhibitors protected tissues from damage and killed bacteria. Also promising reports concerning the use of HtrA as a protective antigen in several disease models have recently been published. Conclusion: The findings of this review suggest that the exported HtrA proteins are very attractive therapeutic targets due to their accessibility, significance in virulence and immunogenicity. However, further extensive studies are still needed to develop a safe antimicrobial treatment.Export Options
About this article
Cite this article as:
The Extracellular Bacterial HtrA Proteins as Potential Therapeutic Targets and Vaccine Candidates, Current Medicinal Chemistry 2017; 24 (20) . https://dx.doi.org/10.2174/0929867323666161223145825
DOI https://dx.doi.org/10.2174/0929867323666161223145825 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Preface
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Insights into Airway Infections by Enterococci: A Review
Recent Patents on Anti-Infective Drug Discovery Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD
Current Drug Targets Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Protection of Blood Brain Barrier Integrity and Modulation of Inflammatory Mediators During Treatment of Pneumococcal Meningitis with Daptomycin or Ceftriaxone
Current Neurovascular Research Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Novel Synthetic Compounds as Potential Anticryptococcal Agents
Current Organic Synthesis Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Recent Studies on the Care of First Febrile Urinary Tract Infection in Infants and Children for the Pediatric Hospitalist
Reviews on Recent Clinical Trials Structure-Activity Relationship of Dicoumarol Derivatives as anti- Staphylococcus aureus (Staph Infection) Agents
Anti-Infective Agents Assays to Predict Drug Permeation Across the Blood-Brain Barrier, and Distribution to Brain
Current Drug Metabolism Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Development of Reverse Phase Ultra-fast Liquid Chromatography Using Ion-pairing Reagent for Quantitative Assessment of Ceftriaxone in Rat Serum and Cerebrospinal Fluid
Current Pharmaceutical Analysis Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science